Outlook Therapeutics (OTLK) Net Income towards Common Stockholders: 2015-2020
Historic Net Income towards Common Stockholders for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$9.9 million.
- Outlook Therapeutics' Net Income towards Common Stockholders rose 3.28% to -$9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$48.9 million, marking a year-over-year decrease of 35.61%. This contributed to the annual value of -$75.4 million for FY2024, which is 27.78% down from last year.
- Latest data reveals that Outlook Therapeutics reported Net Income towards Common Stockholders of -$9.9 million as of Q3 2020, which was down 229.09% from -$3.0 million recorded in Q2 2020.
- Over the past 5 years, Outlook Therapeutics' Net Income towards Common Stockholders peaked at -$3.0 million during Q2 2020, and registered a low of -$30.2 million during Q2 2016.
- Its 3-year average for Net Income towards Common Stockholders is -$10.5 million, with a median of -$9.9 million in 2020.
- In the last 5 years, Outlook Therapeutics' Net Income towards Common Stockholders tumbled by 142.88% in 2016 and then soared by 82.34% in 2017.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Net Income towards Common Stockholders stood at -$19.1 million in 2016, then increased by 7.18% to -$17.7 million in 2017, then spiked by 44.19% to -$9.9 million in 2018, then slumped by 86.79% to -$18.5 million in 2019, then climbed by 3.28% to -$9.9 million in 2020.
- Its last three reported values are -$9.9 million in Q3 2020, -$3.0 million for Q2 2020, and -$17.5 million during Q1 2020.